Enlivex Therapeutics Ltd
NASDAQ:ENLV

Watchlist Manager
Enlivex Therapeutics Ltd Logo
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Watchlist
Price: 1.23 USD -0.81%
Market Cap: 27m USD
Have any thoughts about
Enlivex Therapeutics Ltd?
Write Note

Enlivex Therapeutics Ltd
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Enlivex Therapeutics Ltd
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Additional Paid In Capital
$144.4m
CAGR 3-Years
3%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Additional Paid In Capital
$121.1m
CAGR 3-Years
17%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Additional Paid In Capital
$266.6m
CAGR 3-Years
8%
CAGR 5-Years
8%
CAGR 10-Years
5%
Urogen Pharma Ltd
NASDAQ:URGN
Additional Paid In Capital
$793.9m
CAGR 3-Years
19%
CAGR 5-Years
15%
CAGR 10-Years
N/A
B
Bonus Biogroup Ltd
TASE:BONS
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pluri Inc
NASDAQ:PLUR
Additional Paid In Capital
$421.1m
CAGR 3-Years
3%
CAGR 5-Years
9%
CAGR 10-Years
9%
No Stocks Found

Enlivex Therapeutics Ltd
Glance View

Market Cap
25.7m USD
Industry
Biotechnology

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

ENLV Intrinsic Value
1.18 USD
Overvaluation 4%
Intrinsic Value
Price

See Also

What is Enlivex Therapeutics Ltd's Additional Paid In Capital?
Additional Paid In Capital
144.4m USD

Based on the financial report for Jun 30, 2024, Enlivex Therapeutics Ltd's Additional Paid In Capital amounts to 144.4m USD.

What is Enlivex Therapeutics Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
32%

Over the last year, the Additional Paid In Capital growth was 5%. The average annual Additional Paid In Capital growth rates for Enlivex Therapeutics Ltd have been 3% over the past three years , 32% over the past five years .

Back to Top